
- February 2012 Infectious Disease
- Volume 78
- Issue 2
New Drugs of 2011, Part 2
Pharmacy Times Office of Continuing Professional Education
Michael A. Mancano, PharmD
Clinical Professor of Pharmacy Practice
Interim Chair, Department of Pharmacy Practice
Temple University School of Pharmacy; Philadelphia, PA
Clinical Consultant, Department of Pharmacy
Pennsylvania Hospital; Philadelphia, PA
Michael A. Mancano, PharmD, has no relevant affiliations or financial relationships to disclose.
Judy V. Lum, MPA; Ann C. Lichti, CCMEP; and Donna Fausak of the Pharmacy Times Office of Continuing Professional Education have no relevant affiliations or financial relationships to disclose related to this activity.
Educational Objectives
Upon completing the program, participants should be able to:
- Discuss the clinical indications of 8 new drugs approved by the FDA in 2011.
- Explain the mechanisms of action of the drugs discussed within this program.
- Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
- Identify the most common adverse reactions for the discussed new drug approvals.
- Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: February 10, 2012
Expiration date: February 10, 2014
Estimated time to complete activity: 2.0 hours
Fee: There is no charge for taking this course online.
Click
Articles in this issue
over 14 years ago
Personalized Medicine Brings Pharmacy Science Back to the Futureover 14 years ago
Health Care Reform...Disruptive Changes?over 14 years ago
A Decade of "Smart" Infusion Pumpsover 14 years ago
Overactive Bladder Management: Challenges and Opportunitiesover 14 years ago
Infectious Diseases Watchover 14 years ago
Diabetes Watchover 14 years ago
Cold Watchover 14 years ago
Tech Product Newsover 14 years ago
Technology Newsover 14 years ago
The Evolution of Specialty Pharmacy





































































































































